Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hypogonadism

ClinicalTrials.gov lists 432 trials for Hypogonadism or a narrower condition beneath it. Repros Therapeutics Inc. has the most among industry and government lead sponsors, with 16.

MeSH D007006 Endocrine System Diseases C19
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 41 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 86 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 65 Phase 4 Phase 4 79 Not applicable Not applicable 47 Observational Observational 100 Phase 1 Phase 1 41 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 86 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 65 Phase 4 Phase 4 79 Not applicable Not applicable 47 Observational Observational 100

Trials per phase

316 of the 432 trials are tagged with Hypogonadism itself; the rest are tagged with a narrower condition beneath it.

Get the Hypogonadism report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hypogonadism trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 27

1991: 1 trials (Observational 1) 1993: 2 trials (Observational 2) 1994: 1 trials (Not applicable 1) 1995: 1 trials (Not applicable 1) 1997: 2 trials (Not applicable 1, Phase 2 1) 1999: 4 trials (Observational 2, Not applicable 1, Phase 1 1) 2001: 6 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 3) 2002: 7 trials (Observational 1, Not applicable 2, Phase 3 2, Phase 2 1, Phase 1 1) 2003: 3 trials (Phase 3 2, Phase 2/3 1) 2004: 14 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 2, Phase 2 6, Phase 1 2) 2005: 14 trials (Observational 3, Not applicable 1, Phase 4 3, Phase 3 3, Phase 2 4) 2006: 22 trials (Observational 3, Phase 4 5, Phase 3 3, Phase 2 9, Phase 1 2) 2007: 19 trials (Observational 5, Not applicable 3, Phase 4 2, Phase 3 4, Phase 2 4, Phase 1 1) 2008: 19 trials (Observational 2, Phase 4 8, Phase 3 4, Phase 2 3, Phase 1 2) 2009: 18 trials (Observational 5, Phase 4 5, Phase 2/3 2, Phase 2 3, Phase 1 3) 2010: 18 trials (Observational 3, Not applicable 2, Phase 4 4, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2011: 14 trials (Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 7, Phase 1 2) 2012: 27 trials (Observational 9, Not applicable 3, Phase 4 4, Phase 3 8, Phase 2 3) 2013: 21 trials (Observational 6, Not applicable 2, Phase 4 3, Phase 3 4, Phase 2 2, Phase 1/2 1, Phase 1 3) 2014: 23 trials (Observational 3, Not applicable 2, Phase 4 3, Phase 3 7, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 4) 2015: 18 trials (Observational 6, Not applicable 3, Phase 4 3, Phase 3 3, Phase 2 3) 2016: 27 trials (Observational 6, Not applicable 3, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 3) 2017: 20 trials (Observational 6, Not applicable 3, Phase 4 4, Phase 3 4, Phase 2 2, Phase 1/2 1) 2018: 16 trials (Observational 5, Not applicable 2, Phase 4 3, Phase 3 3, Phase 1 3) 2019: 9 trials (Not applicable 1, Phase 4 3, Phase 2 4, Phase 1 1) 2020: 12 trials (Observational 3, Not applicable 1, Phase 4 6, Phase 3 1, Phase 1 1) 2021: 17 trials (Observational 4, Not applicable 1, Phase 4 5, Phase 2 6, Phase 1 1) 2022: 18 trials (Observational 6, Not applicable 3, Phase 4 3, Phase 3 1, Phase 2 3, Phase 1 2) 2023: 10 trials (Observational 5, Not applicable 2, Phase 3 2, Phase 2 1) 2024: 14 trials (Observational 5, Not applicable 1, Phase 4 3, Phase 3 1, Phase 2 1, Phase 1/2 2, Phase 1 1) 2025: 15 trials (Observational 3, Not applicable 1, Phase 4 3, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 14
2025 15
2024 14
2023 10
2022 18
2021 17
2020 12
2019 9
2018 16
2017 20

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 16 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 22 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 293 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hypogonadism trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 41
Phase 1/2 8
Phase 2 86
Phase 2/3 6
Phase 3 65
Phase 4 79
Not applicable 47
Observational 100

How many Hypogonadism trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 16
Recruiting 37
Enrolling by invitation 7
Active, not recruiting 5
Completed 278

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hypogonadism trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Repros Therapeutics Inc. 16
Clarus Therapeutics, Inc. 11
Acerus Pharmaceuticals Corporation 7
Bayer 7
Rhythm Pharmaceuticals, Inc. 7

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Hypogonadism? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Enclomiphene 16
GnRH 15
Anastrozole 8
Estradiol 7
Testosterone Enanthate 6

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Testosteron 65
Testosterone undecannoate 41
Testosterone Gel 27
r-hCG 13
Kisspeptin 112-121 9

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hypogonadism trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Other noncardiovascular serious adverse events 88 1
PNEUMONIA 72 1
CORONARY ARTERY DISEASE 69 2
ATRIAL FIBRILLATION 68 1
ACUTE MYOCARDIAL INFARCTION 63 3

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hypogonadism? (351)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology 2025 Yes
Single-arm study of testosterone gel replacement therapy and ambulatory blood pressure outcomes in men with hypogonadism. Andrology 2025 Yes
Castration Levels of Testosterone Results in Atrophy of Androgen-sensitive Perineal Muscles: A Potential Biomarker for Male Hypogonadism. Urology 2025 Yes
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes, obesity & metabolism 2025 Yes
PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/β-CATENIN Pathway in Testosterone-Treated Hypogonadal Men. Biomolecules 2025 Yes

Showing 5 of 351 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages